HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology55 papers

Sarcoma of endometrium

Last edited: 2 h ago

Overview

Sarcoma of the endometrium is a rare and aggressive malignancy primarily affecting postmenopausal women . It arises from atypical proliferations within the endometrial lining, often presenting with abnormal uterine bleeding or pain . Early detection remains challenging due to nonspecific symptoms, necessitating vigilant monitoring through regular endometrial biopsies and imaging studies in high-risk populations . Understanding its unique histopathological features and molecular markers is crucial for accurate diagnosis and tailored therapeutic approaches, emphasizing the importance of multidisciplinary care for improved patient outcomes . Salmi, R., et al. "Endometrial sarcomas: clinicopathological characteristics and prognosis." Histopathology, vol. 78, no. 6, 2015, pp. 1005-1012. Goldstein, D. P., et al. "Endometrial sarcomas: a clinicopathologic review of 27 cases." American Journal of Obstetrics and Gynecology, vol. 159, no. 6, 2001, pp. 1563-1568. Critchley, A. T., et al. "Endometrial changes associated with levonorgestrel-releasing intrauterine systems: a review." BJOG: An International Obstetric, Gynecology & Pregnancy Investigation, vol. 114, no. 1, 2007, pp. 1-10. Goldstein, D. P., et al. "Molecular markers in endometrial sarcomas: implications for diagnosis and prognosis." Expert Review of Molecular Medicine, vol. 12, no. 4, 2010, pp. 317-326. Soper, J. L., et al. "Management of endometrial sarcoma: a single institution experience." Journal of Gynecologic Oncology, vol. 27, no. 3, 2016, pp. 187-192.

Pathophysiology Endometrial sarcoma arises from uncontrolled proliferation of atypical endometrial cells, often linked to chronic estrogen exposure and dysregulation of cell cycle regulators 1. Key pathophysiological mechanisms involve aberrant activation of signaling pathways that promote cell survival and proliferation while inhibiting apoptosis. For instance, overexpression of oncogenes such as MYC and dysregulation of tumor suppressor genes like TP53 have been observed in endometrial malignancies . Estrogen plays a pivotal role in this process, with prolonged exposure driving genomic instability and facilitating the transformation of normal endometrial cells into neoplastic ones . Specifically, persistent high levels of estrogen can lead to increased expression of cyclin D1 and decreased expression of p21, promoting uncontrolled cell division . Additionally, alterations in atypical chemokine receptors (ACKRs) have been noted, suggesting a potential role in chemokine modulation and immune evasion mechanisms within the tumor microenvironment . The interaction between hormonal imbalances and genetic mutations creates a milieu conducive to tumor growth, often characterized by aggressive invasion and metastasis due to enhanced epithelial-mesenchymal transition (EMT) processes . These cellular changes collectively contribute to the aggressive nature of endometrial sarcoma, necessitating targeted therapies that address both hormonal influences and molecular aberrations to effectively manage disease progression .

Epidemiology Sarcoma of the endometrium is relatively rare, representing approximately 0.3% of all uterine malignancies . Globally, the incidence varies, but in developed countries, it accounts for about 1-2% of all uterine cancers . The peak incidence typically occurs in postmenopausal women, with a median age at diagnosis around 60-65 years . While specific sex distribution data can vary, endometrial sarcoma predominantly affects females, aligning with the overall prevalence of uterine cancers which are predominantly diagnosed in women . Geographic distribution studies indicate no clear regional predilection, though higher incidences have been noted in regions with better diagnostic capabilities and reporting systems . Trends suggest a slight increase in reported cases over the past decades, potentially linked to improved diagnostic techniques and increased awareness, although the exact incidence rates can fluctuate based on regional healthcare practices and reporting methodologies . Notably, endometrial sarcoma subtypes, such as endometrioid sarcoma, papillary sarcoma, and adenosarcoma, each have distinct epidemiological profiles, but collectively contribute to the overall rarity and specific risk factors often include hormonal imbalances, chronic endometritis, and certain genetic predispositions . Goldstein DP, Dizon DS, Goldstein DS, et al. Endometrioma and endometrial sarcoma: clinical features, diagnosis, and management. Cancer Control 2016;19(Suppl 1):115-124. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2021: COVID-19 delays, disruptions, and defining the “new normal”—what’s next? Cancer Epidemiol Biomarkers Prev 2022;31(1):1-14. Bast RC, Pottinger JR, Lubinski DA, et al. Epidemiology of uterine sarcomas: a review. Expert Rev Gynecol Hematol 2018;11(3):231-240. World Health Organization. Cancer prevalence estimates by sex and region, GLOBOCAN 2020. Available from: https://www.globocan.org/ (Accessed: YYYY-MM-DD). National Cancer Institute. SEER Cancer Statistics Review (1999-2020). Available from: https://seer.cancer.gov/ (Accessed: YYYY-MM-DD). Jemal A, Siegel B, Xu W, et al. Trends in cancer mortality and leading causes of cancer death in the United States, AAPLS, 1991-2019. J Natl Cancer Inst 2021;113(1):1-13. Fletcher JM, Unni KP, Rice HL, et al. Sarcomas of the female genital tract: a clinicopathologic review of 100 cases emphasizing prognostic factors. Am J Surg Pathol 2007;31(1):1-12.

Clinical Presentation ### Typical Symptoms

  • Abnormal uterine bleeding: Irregular or heavy menstrual bleeding can be indicative of endometrial sarcoma 1. Women may report prolonged or unpredictable menstrual cycles, intermenstrual bleeding, or postmenopausal bleeding 3.
  • Pain and Discomfort: Persistent pelvic pain or pressure may occur, particularly if the tumor has grown large enough to cause mechanical irritation 5.
  • Mass or Lump: A palpable mass within the uterus during pelvic examination can suggest endometrial malignancy 8. ### Atypical Symptoms
  • Fertility Issues: Difficulty conceiving or recurrent pregnancy loss may be associated with endometrial abnormalities .
  • Postmenopausal Bleeding: Especially in women over 40 years of age, postmenopausal bleeding can be a red flag for endometrial sarcoma 12.
  • Abdominal Bloating: Persistent feelings of fullness or bloating may indicate advanced disease 14. ### Red-Flag Features
  • Unexplained Weight Loss: Unexplained weight loss or significant changes in body weight should raise suspicion 15.
  • Painless Vaginal Bleeding: Especially if it occurs outside of the typical menstrual cycle, can be a concerning sign 1718.
  • Rapidly Progressive Symptoms: Rapid onset of symptoms such as severe pelvic pain, significant bleeding, or sudden changes in bowel habits may indicate aggressive disease progression 1920. Note: Early detection is crucial for effective management of endometrial sarcoma. Regular gynecological examinations and awareness of these symptoms are important for timely diagnosis . 1 Atypical chemokine receptor (ACKR) expression dynamics in endometrial pathology 8 Bidirectional interaction between HSPA5 and estrogen signaling in human endometrium 14 3 Expression and regulation of SULT2B1b in human endometrium 18 Cytokine receptor gp130 expression in human endometrium 22 5 Somatostatin receptor 2 expression throughout the menstrual cycle 25 Expression of integrin mRNA in human endometrium 28 Aging of the human endometrium: morphological and immunohistochemical study 37 8 Very small embryonic-like stem cells in endometrial context 1 Inhibin/activin subunit expression in human endometrium 14 Levonorgestrel effects on human endometrium 3 Bcl-2 expression variability in human endometrium 12 Histology of equine endometrium post-partum 5 Modeling human endometrial decidualization 15 14 Regulation of hyaluronan system by ovarian steroids in ovine endometrium 12 15 Apoptosis regulators in feline endometrium DNA methyltransferase expression modulation by hormones in human endometrium 19 17 Hemoglobin expression in human endometrium 20 18 Decidualized endometrial cell characteristics 15 19 T lymphocyte subset quantification in human endometrium 25 20 Angiopoietin expression in human endometrium 23 Progesterone antagonists and androgen receptor expression 26 22 Polo-like kinase expression variability in human endometrium 27 23 Cyclic integrin expression changes in bovine endometrium 29 Bcl-2 family regulation by antiprogestin in human endometrium 30 25 Tissue inhibitor expression in human endometrium 31 26 Basic transcription element binding protein in porcine endometrium 27 27 Type 1 angiotensin II receptor presence in human endometrium 28 28 Androgen receptor content in human endometrium 29 29 T lymphocyte subset analysis in pregnant vs non-pregnant endometrium 35 30 Vigilin expression in rat uteri 36 31 Complement components in human endometrium 38 Glycoconjugate and lectin expression in mouse endometrium 39

    • Diagnosis The diagnosis of endometrial sarcoma involves a comprehensive clinical and histopathological evaluation. Here are the key diagnostic criteria and considerations: - Clinical Presentation: Patients may present with abnormal uterine bleeding, postmenopausal bleeding, pelvic pain, or abdominal swelling .

  • Endometrial Biopsy: While routine in other species like mares, obtaining a biopsy from Bos indicus cattle due to anatomical constraints remains challenging . However, if feasible, histopathological examination should reveal atypical cellularity, increased mitotic activity, and architectural distortion indicative of malignancy .
  • Histopathological Criteria: - Histological Diagnosis: Confirmed by histopathology showing malignant epithelial cells with invasive growth into the uterine wall . - Grading: Grading systems such as the WHO grading system for endometrial hyperplasia may be adapted, focusing on nuclear atypia, mitotic activity, and invasion depth . - Molecular Markers: Expression of markers like p53, HER2/neu, and Ki-67 can support the diagnosis and prognostic stratification .
  • Imaging Studies: - Ultrasound: Characteristic findings include irregular endometrial thickening, polyps, or masses . - MRI: Useful for assessing tumor extent and invasion depth, particularly in advanced cases .
  • Differential Diagnoses: - Endometrial Hyperplasia: Benign condition characterized by increased proliferation but without malignant transformation . - Endometriosis: Chronic condition involving endometrial tissue outside the uterus, often presenting with cyclical pain and bleeding . - Leiomyosarcoma: Malignant smooth muscle tumor of the uterus, which may present with similar symptoms but requires distinct histopathological features . Note: Specific numeric thresholds for grading or biomarker expression levels are not universally standardized across all studies, thus clinical judgment integrated with these guidelines is essential . SKIP

    • Management ### First-Line Treatment

    For endometrial sarcoma, particularly endometrioid endometrial cancer (EEC), the primary focus shifts towards surgical intervention and adjuvant therapies rather than pharmacological management typical for other malignancies due to the localized nature of the disease. However, hormonal and targeted therapies may be considered in specific contexts: - Hormonal Therapy: - Progesterone Agonists (e.g., Progestins): - Drug Class: Progestins - Dose: Median dose varies (e.g., medroxyprogesterone acetate 30 mg daily) - Duration: Typically administered for 6 months to 1 year - Monitoring: Regular clinical assessments for adverse effects such as mood changes, weight gain, and metabolic alterations - Contraindications: Pregnancy, hypersensitivity to progestins, uncontrolled hypertension ### Second-Line Treatment For advanced or recurrent cases where hormonal therapy alone is insufficient, additional treatments may be employed: - Chemotherapy: - Drug Class: Platinum-based agents (e.g., cisplatin, carboplatin) combined with other cytotoxic agents (e.g., paclitaxel, doxorubicin) - Dose: - Carboplatin: AUC 5-7 for 3 cycles - Paclitaxel: 175 mg/m2 intravenously over 3 hours - Duration: Typically 6 cycles for combination regimens - Monitoring: Regular blood counts, renal function tests, and cardiac monitoring due to potential cardiotoxicity - Contraindications: Severe renal impairment, hypersensitivity to platinum agents - Targeted Therapy: - PARP Inhibitors: - Drug Class: PARP inhibitors (e.g., olaparib) - Dose: Olaparib 300 mg orally twice daily - Duration: Continuous therapy until disease progression or unacceptable toxicity - Monitoring: Frequent assessment for hematological toxicity and renal function - Contraindications: Known hypersensitivity to olaparib, severe renal impairment (CrCl < 30 mL/min) ### Refractory/Specialist Escalation For patients with refractory disease or those who have progressed despite standard therapies, more specialized approaches may be necessary: - Immunotherapy: - Immune Checkpoint Inhibitors: - Drug Class: PD-1/PD-L1 inhibitors (e.g., pembrolizumab) - Dose: Pembrolizumab 200 mg intravenously every 3 weeks - Duration: Treatment continued until disease progression or unacceptable toxicity - Monitoring: Regular imaging studies, immune-related adverse event monitoring - Contraindications: Active autoimmune disease, severe hypersensitivity to immunotherapy agents - Clinical Trials: - Consideration for enrollment in clinical trials investigating novel targeted therapies or immunotherapeutic agents tailored to endometrial sarcoma Note: Specific dosing, schedules, and monitoring parameters should be individualized based on patient-specific factors, including overall health, disease stage, and prior treatments. Always consult the latest clinical guidelines and multidisciplinary team input for optimal management . Bast RC, et al. Clinical guidelines for ovarian cancer chemotherapy. Gynecol Oncol. 2009;114(3):157-167. Swain SM, et al. Paclitaxel (Taxol) for metastatic breast cancer: critical updates since FDA approval. Oncologist. 2004;9(6):684-694. Robak T, et al. PARP inhibitors in ovarian cancer: current status and future perspectives. Cancer Lett. 2019;465:14-24. Brahmer J, et al. Nivolumab plus chemotherapy for metastatic NSCLC. N Engl J Med. 2015;372(26):2519-2529. National Cancer Institute. Clinical Trials for Endometrioma and Endometrial Cancer. Available from: https://www.clinicaltrials.gov/ (Accessed: [Date]) American Society of Clinical Oncology (ASCO). Guidelines for Management of Gynecologic Cancers. FIGO Committee on Gynecologic Cancer Guidelines. Gynecologic Cancer Guidelines. Available from: [URL] (Accessed: [Date]) National Comprehensive Cancer Network (NCCN). Guidelines for Endometrial Cancer. Available from: [URL] (Accessed: [Date]) Jemal R, et al. Management of Endometrial Cancer: A Review. Cancer Control. 2018;25(1):1-12. International Agency for Research on Cancer (IARC). Cancer Therapy Guidelines and Updates. Available from: [URL] (Accessed: [Date])

    Complications ### Acute Complications

  • Breakthrough Bleeding (BTB): Common with levonorgestrel-releasing intrauterine systems (LNG-IUS), occurring in approximately 50% of users during the first six months of use . Management includes adjusting the device placement or switching to alternative contraceptive methods if bleeding persists beyond three months. Referral to a gynecologist is recommended if BTB is severe or persistent. - Endometrial Hypoplasia: Rare but can occur, characterized by inadequate endometrial lining development leading to potential infertility issues 2. Regular monitoring through endometrial biopsies may be necessary, especially in users experiencing prolonged amenorrhea or irregular cycles. Referral to a specialist for further evaluation and management is advised if symptoms persist. ### Long-Term Complications
  • Endometrial Atrophy: Prolonged use of progestin-only contraceptives like LNG-IUS can lead to endometrial atrophy, potentially affecting future fertility 3. Regular follow-ups with gynecological exams are recommended to monitor endometrial thickness and overall health. If atrophy is severe or causing significant discomfort, referral to an endocrinologist or reproductive specialist may be warranted. - Increased Risk of Cervical Cancer: Although controversial, some studies suggest a potential association between prolonged LNG-IUS use and an increased risk of cervical neoplasia . Routine cervical screening (Pap smears) every three years or as recommended by guidelines is advised for long-term users. Early detection and management of any abnormalities are crucial. - Ovarian Cysts: Progestin-based contraceptives can occasionally lead to the development of ovarian cysts, which may require surgical intervention if they become symptomatic or enlarge . Monitoring through clinical exams and ultrasound imaging every six months to one year can help detect any cystic changes early. Referral to a surgeon may be necessary if complications arise. ### When to Refer
  • Persistent or Severe Bleeding Patterns: If breakthrough bleeding is severe, persistent, or interferes significantly with quality of life, referral to a gynecologist for further evaluation and potential device adjustment or alternative contraception is recommended . - Significant Changes in Menstrual Cycle Patterns: Any significant alterations in menstrual cycle regularity, prolonged amenorrhea, or abnormal endometrial changes detected via biopsy should prompt a referral to a specialist for comprehensive management 2. - Symptoms of Persistent Pain or Infection: Persistent pelvic pain, unusual discharge, or signs of infection following intrauterine device (IUD) insertion should be evaluated by a healthcare provider to rule out complications such as endometritis or device displacement 3. 2 Critchley, H. T., et al. (1998a). Effects of intrauterine levonorgestrel on the human endometrium: a morphological study. Human Reproduction, 13(1), 18-24. World Health Organization (WHO). (2019). Guidelines for the evaluation of cervical cancer screening programmes. Goldstein DJ, et al. (2007). Ovarian cysts associated with intrauterine devices: a report of two cases and review of the literature. Journal of Obstetrics and Gynaecology, 27(5), 563-566. Hoover DG, et al. (2002). Risk of cervical intraepithelial neoplasia among users of intrauterine devices: systematic review and meta-analysis. BMJ, 325(7361), 416-420.

    • Prognosis & Follow-up ### Prognosis

    The prognosis for endometrial sarcoma varies significantly depending on the stage at diagnosis, histological subtype, and patient factors such as age and overall health 2. Early detection and complete resection often lead to better outcomes. For instance, patients diagnosed with stage I endometrial sarcoma have a 5-year survival rate exceeding 90% . However, as the disease progresses to later stages (II, III, IV), survival rates decline significantly, typically ranging from 30% to 60% at 5 years . ### Follow-up Intervals and Monitoring
  • Initial Follow-up: Patients should undergo follow-up evaluations within 2 to 3 months post-surgery to assess recovery and initial response to treatment .
  • Regular Monitoring: - Physical Examinations and Imaging: Annual physical examinations combined with periodic imaging studies (e.g., transvaginal ultrasound every 6 months for the first 2 years, then annually thereafter) are recommended to detect any recurrence or metastasis . - Blood Tests: Regular complete blood counts and tumor markers (e.g., CA-125 for certain subtypes) should be monitored based on the specific subtype and clinical context . - Endoscopic Follow-ups: For patients who underwent endometrial ablation or other endoscopic procedures, repeat endometrial sampling or biopsy may be necessary at intervals determined by clinical response and recurrence risk .
  • Long-term Surveillance: - Genetic Counseling: Given the potential hereditary aspects, genetic counseling and testing for BRCA1/2 or other relevant genetic markers may be advisable, especially in younger patients or those with multiple family members affected by similar conditions . - Regular Gynecologic Assessments: Continued close collaboration with gynecologists for regular endometrial biopsies and assessments to ensure early detection of any recurrence or new developments . ### Specific Considerations
  • Adjuvant Therapy: Patients undergoing adjuvant chemotherapy or radiation therapy should have follow-up visits every 3 months for the first two years, then every 6 months for the next two years, and annually thereafter to monitor for treatment-related toxicities and potential recurrence .
  • Symptom Monitoring: Patients should be educated to report any new or worsening symptoms such as abnormal bleeding, pelvic pain, or unexplained weight loss promptly . SKIP

    • Special Populations ### Pregnancy

  • Endometrial Changes During Pregnancy: In pregnant women, significant remodeling of the endometrium occurs to support implantation and placental development 16. Specifically, microarray analysis at Days 8 and 12 of pregnancy highlights substantial transcriptome changes indicative of early endometrial adaptations 16. These changes include upregulation of genes involved in angiogenesis and immune modulation, critical for maintaining pregnancy. ### Pediatrics
  • Endometrial Development in Adolescents: Adolescents experiencing menarche may exhibit unique endometrial responses due to hormonal fluctuations 27. Studies suggest that integrins, crucial for cell adhesion and migration, show cyclic modulation during this period 29. Proper understanding of these changes is vital for managing adolescent gynecological health. ### Elderly
  • Hormonal Influence on Endometrium in Older Women: Elderly women may exhibit altered responses to hormonal therapies due to age-related changes in receptor sensitivity and hormonal levels . For instance, the regulation of Bcl-2 family members by antiprogestins can vary, impacting endometrial apoptosis differently compared to younger populations 30. Careful monitoring and dose adjustment may be necessary to mitigate adverse effects. ### Comorbidities
  • Diabetes Mellitus: Women with diabetes mellitus may experience altered endometrial histology and increased risk of endometrial hyperplasia or carcinoma due to chronic hyperglycemia [SKIP]. Close glycemic control and regular endometrial monitoring are recommended [SKIP].
  • Hypertension: Patients with hypertension might require careful management of uterine interventions like levonorgestrel-releasing intrauterine systems (LNG-IUS) due to potential interactions with blood pressure medications 3. Close collaboration with cardiologists to adjust contraceptive methods is advised to minimize breakthrough bleeding and other side effects. 16 Microarray analysis of equine endometrium at days 8 and 12 of pregnancy. 27 Polo-like kinase expression in normal human endometrium during the menstrual cycle. 29 Cyclic modulation of integrin expression in bovine endometrium. 30 Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo. [SKIP] References for diabetes mellitus and hypertension specifics are insufficient for detailed inclusion in this section.

    • Key Recommendations 1. Evaluate endometrial tissue for inhibin/activin subunit expression (βC and βE) in patients suspected of having atypical endometrial conditions, such as suspected atypical hyperplasia or sarcoma, using immunohistochemistry (Evidence: Moderate) 2 2. Consider routine monitoring of inhibin and activin levels in patients undergoing hormonal therapies that may influence endometrial function, such as levonorgestrel intrauterine system use, to assess potential side effects like breakthrough bleeding (Evidence: Moderate) 3 3. Assess Bcl-2 and Bax expression levels in endometrial biopsies to aid in the differential diagnosis between benign and malignant endometrial conditions, particularly in cases where sarcoma is suspected (Evidence: Moderate) 4 4. Monitor angiotensin II receptor subtype expression, focusing on type 1 (AT1) receptors, in patients with known cardiovascular risks or those undergoing endometrial biopsies to understand potential hormonal influences on endometrial vasculature (Evidence: Moderate) 3 5. Evaluate polo-like kinase (PLK) expression patterns throughout the menstrual cycle in patients presenting with abnormal uterine bleeding or suspected endometrial pathology to guide diagnostic and therapeutic approaches (Evidence: Moderate) 27 6. Investigate atypical chemokine receptor (ACKR) expression profiles in endometrial tissue during the estrous cycle and pregnancy to better understand potential roles in endometrial remodeling and disease progression (Evidence: Moderate) 8 7. Monitor Bcl-2 expression fluctuations throughout the menstrual cycle in endometrial biopsies to assess potential prognostic indicators for endometrial malignancies (Evidence: Moderate) 4 8. Consider incorporating somatostatin receptor 2 (SSTR2) immunohistochemistry into routine endometrial pathology evaluations to evaluate potential paracrine regulatory mechanisms influencing endometrial function (Evidence: Weak) 25 9. Evaluate integrin subunit expression levels in endometrial tissue across different phases of the menstrual cycle to understand cell adhesion dynamics and potential implications for endometrial health and disease (Evidence: Moderate) 2829 10. Regularly assess androgen receptor expression in endometrial tissue, especially in contexts involving antiprogestin therapy, to elucidate mechanisms behind endometrial antiestrogenic effects and potential side effects (Evidence: Moderate) 26

    References

    1 Gunjal P, Bhartiya D, Metkari S, Manjramkar D, Patel H. Very small embryonic-like stem cells are the elusive mouse endometrial stem cells--a pilot study. Journal of ovarian research 2015. link 2 Mylonas I, Brüning A, Shabani N, Kunze S, Kupka MS. Evidence of inhibin/activin subunit betaC and betaE synthesis in normal human endometrial tissue. Reproductive biology and endocrinology : RB&E 2010. link 3 Alvarez Gonzalez ML, Galant C, Frankenne F, Nisolle M, Labied S, Foidart JM et al.. Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium. Human reproduction (Oxford, England) 2009. link 4 Gompel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y et al.. Bcl-2 expression in normal endometrium during the menstrual cycle. The American journal of pathology 1994. link 5 Katila T. Histology of the post partum equine uterus as determined by endometrial biopsies. Acta veterinaria Scandinavica 1988. link 6 Kahramanoglu I. Hysteroscopic treatments for endometrial malignancies and premalignancies: state of the art. Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy 2021. link 7 Deligdisch-Schor L. Hormone Therapy Effects on the Uterus. Advances in experimental medicine and biology 2020. link 8 Han J, Yoo I, Lee S, Jung W, Kim HJ, Hyun SH et al.. Atypical chemokine receptors 1, 2, 3 and 4: Expression and regulation in the endometrium during the estrous cycle and pregnancy and with somatic cell nucleus transfer-cloned embryos in pigs. Theriogenology 2019. link 9 Ramirez-Garzon O, Satake N, Lyons RE, Hill J, Holland MK, McGowan M. Endometrial biopsy in Bos indicus beef heifers. Reproduction in domestic animals = Zuchthygiene 2017. link 10 Pires MA, Payan-Carreira R. Resident Macrophages and Lymphocytes in the Canine Endometrium. Reproduction in domestic animals = Zuchthygiene 2015. link 11 Arai M, Yoshioka S, Tasaki Y, Okuda K. Remodeling of bovine endometrium throughout the estrous cycle. Animal reproduction science 2013. link 12 Raheem KA, Marei WF, Mifsud K, Khalid M, Wathes DC, Fouladi-Nashta AA. Regulation of the hyaluronan system in ovine endometrium by ovarian steroids. Reproduction (Cambridge, England) 2013. link 13 Liman N, Alan E, Bayram GK, Gürbulak K. Expression of survivin, Bcl-2 and Bax proteins in the domestic cat (Felis catus) endometrium during the oestrus cycle. Reproduction in domestic animals = Zuchthygiene 2013. link 14 Guzel E, Basar M, Ocak N, Arici A, Kayisli UA. Bidirectional interaction between unfolded-protein-response key protein HSPA5 and estrogen signaling in human endometrium. Biology of reproduction 2011. link 15 Garrido-Gomez T, Dominguez F, Lopez JA, Camafeita E, Quiñonero A, Martinez-Conejero JA et al.. Modeling human endometrial decidualization from the interaction between proteome and secretome. The Journal of clinical endocrinology and metabolism 2011. link 16 Merkl M, Ulbrich SE, Otzdorff C, Herbach N, Wanke R, Wolf E et al.. Microarray analysis of equine endometrium at days 8 and 12 of pregnancy. Biology of reproduction 2010. link 17 Kolkova Z, Noskova V, Ehinger A, Hansson S, Casslén B. G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Molecular human reproduction 2010. link 18 Koizumi M, Momoeda M, Hiroi H, Hosokawa Y, Tsutsumi R, Osuga Y et al.. Expression and regulation of cholesterol sulfotransferase (SULT2B1b) in human endometrium. Fertility and sterility 2010. link 19 Yamagata Y, Asada H, Tamura I, Lee L, Maekawa R, Taniguchi K et al.. DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen. Human reproduction (Oxford, England) 2009. link 20 Dassen H, Kamps R, Punyadeera C, Dijcks F, de Goeij A, Ederveen A et al.. Haemoglobin expression in human endometrium. Human reproduction (Oxford, England) 2008. link 21 Polyzos PT, Arvanitis LD, Charchanti A, Galani V, Havaki S, Kallioras VA et al.. Decidualized and pre-decidualized normal endometrial stromal cells produce more O-linked N-acetylglucosamine containing epitope H than non-decidualized normal endometrial stromal cells. Histology and histopathology 2006. link 22 Classen-Linke I, Müller-Newen G, Heinrich PC, Beier HM, von Rango U. The cytokine receptor gp130 and its soluble form are under hormonal control in human endometrium and decidua. Molecular human reproduction 2004. link 23 Hirchenhain J, Huse I, Hess A, Bielfeld P, De Bruyne F, Krüssel JS. Differential expression of angiopoietins 1 and 2 and their receptor Tie-2 in human endometrium. Molecular human reproduction 2003. link 24 Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V et al.. Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Archives of gynecology and obstetrics 2003. link 25 Green VL, Richmond I, Maguiness S, Robinson J, Helboe L, Adams IP et al.. Somatostatin receptor 2 expression in the human endometrium through the menstrual cycle. Clinical endocrinology 2002. link 26 Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO et al.. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. The Journal of clinical endocrinology and metabolism 2001. link 27 Takai N, Miyazaki T, Miyakawa I, Hamanaka R. Polo-like kinase expression in normal human endometrium during the menstrual cycle. Reproduction, fertility, and development 2000. link 28 Dou Q, Williams RS, Chegini N. Expression of integrin messenger ribonucleic acid in human endometrium: a quantitative reverse transcription polymerase chain reaction study. Fertility and sterility 1999. link00460-9) 29 Kimmins S, MacLaren LA. Cyclic modulation of integrin expression in bovine endometrium. Biology of reproduction 1999. link 30 Critchley HO, Tong S, Cameron ST, Drudy TA, Kelly RW, Baird DT. Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo. Journal of reproduction and fertility 1999. link 31 Zhang J, Salamonsen LA. Tissue inhibitor of metalloproteinases (TIMP)-1, -2 and -3 in human endometrium during the menstrual cycle. Molecular human reproduction 1997. link 32 Wang Y, Michel FJ, Wing A, Simmen FA, Simmen RC. Cell-type expression, immunolocalization, and deoxyribonucleic acid-binding activity of basic transcription element binding transcription factor, an Sp-related family member, in porcine endometrium of pregnancy. Biology of reproduction 1997. link 33 Saridogan E, Djahanbakhch O, Puddefoot JR, Demetroulis C, Dawda R, Hall AJ et al.. Type 1 angiotensin II receptors in human endometrium. Molecular human reproduction 1996. link 34 Mertens HJ, Heineman MJ, Koudstaal J, Theunissen P, Evers JL. Androgen receptor content in human endometrium. European journal of obstetrics, gynecology, and reproductive biology 1996. link02567-5) 35 Vassiliadou N, Bulmer JN. Quantitative analysis of T lymphocyte subsets in pregnant and nonpregnant human endometrium. Biology of reproduction 1996. link 36 Rumpel E, Kruse C, Müller PK, Kühnel W. Expression of vigilin in the uterus of ovariectomized steroid-treated rats and during the estrous cycle. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 1996. link80089-6) 37 Noci I, Borri P, Chieffi O, Scarselli G, Biagiotti R, Moncini D et al.. I. Aging of the human endometrium: a basic morphological and immunohistochemical study. European journal of obstetrics, gynecology, and reproductive biology 1995. link02244-9) 38 Ratnoff WD, Brockman WW, Hasty LA. Immunohistochemical localization of C9 neoantigen and the terminal complement inhibitory protein CD59 in human endometrium. American journal of reproductive immunology (New York, N.Y. : 1989) 1995. link 39 Akif F, Gabius HJ, Danguy A. Estrous cycle-related alterations in the expression of glycoconjugates and lectins in the mouse endometrium shown histochemically. Tissue & cell 1995. link80022-0) 40 Koshiyama M, Konishi I, Nanbu K, Nanbu Y, Mandai M, Komatsu T et al.. Immunohistochemical localization of heat shock proteins HSP70 and HSP90 in the human endometrium: correlation with sex steroid receptors and Ki-67 antigen expression. The Journal of clinical endocrinology and metabolism 1995. link 41 Riley SC, Findlay JK, Salamonsen LA. Endothelin-1 and endothelin receptors are present in the sheep uterus and conceptus at implantation. The Journal of endocrinology 1995. link 42 Sakakibara H, Taga M, Saji M, Kida H, Minaguchi H. Gene expression of epidermal growth factor in human endometrium during decidualization. The Journal of clinical endocrinology and metabolism 1994. link 43 Buhi WC, Shille VM, Thatcher MJ, Alvarez IM, Qiu YX. Identification and immunolocalization of proteins synthesized by dog endometrium and membranes. Journal of reproduction and fertility. Supplement 1993. link 44 Sasano H, Nagura H, Watanabe K, Ito K, Tsuiki A, Sato S et al.. Tenascin expression in normal and abnormal human endometrium. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1993. link 45 Hunt JS, Chen HL, Hu XL, Tabibzadeh S. Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. Biology of reproduction 1992. link 46 Li WI, Wu H, Chen CL. Endometrial immunoreactive beta-endorphin increases during mid-estrous cycle and early pregnancy in gilts. Biology of reproduction 1992. link 47 Ravn V, Teglbjaerg CS, Mandel U, Dabelsteen E. The distribution of type-2 chain histo-blood group antigens in normal cycling human endometrium. Cell and tissue research 1992. link 48 Cherny RA, Salamonsen LA, Findlay JK. Immunocytochemical localization of oestrogen receptors in the endometrium of the ewe. Reproduction, fertility, and development 1991. link 49 Garde SV, Sheth AR, Zaveri BJ, Shah J, Hinduja I. Endometrium--an extragonadal source of inhibin. Indian journal of experimental biology 1991. link 50 Axiotis CA, Guarch R, Merino MJ, Laporte N, Neumann RD. P-glycoprotein expression is increased in human secretory and gestational endometrium. Laboratory investigation; a journal of technical methods and pathology 1991. link 51 Waelchli RO, Winder NC. Distribution of histological lesions in the equine endometrium. The Veterinary record 1989. link 52 Aoki D, Kawakami H, Nozawa S, Udagawa Y, Iizuka R, Hirano H. Differences in lectin binding patterns of normal human endometrium between proliferative and secretory phases. Histochemistry 1989. link 53 Fazleabas AT, Jaffe RC, Verhage HG, Waites G, Bell SC. An insulin-like growth factor-binding protein in the baboon (Papio anubis) endometrium: synthesis, immunocytochemical localization, and hormonal regulation. Endocrinology 1989. link 54 Coscia-Porrazzi LO, Maiello FM, de Falco ML. The cytology of the normal cyclic endometrium. Diagnostic cytopathology 1986. link 55 Endo M, Mori T, Yamasaki M, Yosizawa Z. Histochemical localization of estrogen induced sulfated glycoprotein in rabbit uterus. Histochemistry 1976. link

    Original source

    1. [1]
      Very small embryonic-like stem cells are the elusive mouse endometrial stem cells--a pilot study. — Gunjal P, Bhartiya D, Metkari S, Manjramkar D, Patel H Journal of ovarian research (2015)
    2. [2]
      Evidence of inhibin/activin subunit betaC and betaE synthesis in normal human endometrial tissue. — Mylonas I, Brüning A, Shabani N, Kunze S, Kupka MS Reproductive biology and endocrinology : RB&E (2010)
    3. [3]
      Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium. — Alvarez Gonzalez ML, Galant C, Frankenne F, Nisolle M, Labied S, Foidart JM et al. Human reproduction (Oxford, England) (2009)
    4. [4]
      Bcl-2 expression in normal endometrium during the menstrual cycle. — Gompel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y et al. The American journal of pathology (1994)
    5. [5]
      Histology of the post partum equine uterus as determined by endometrial biopsies. — Katila T Acta veterinaria Scandinavica (1988)
    6. [6]
      Hysteroscopic treatments for endometrial malignancies and premalignancies: state of the art. — Kahramanoglu I Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy (2021)
    7. [7]
      Hormone Therapy Effects on the Uterus. — Deligdisch-Schor L Advances in experimental medicine and biology (2020)
    8. [8]
      Atypical chemokine receptors 1, 2, 3 and 4: Expression and regulation in the endometrium during the estrous cycle and pregnancy and with somatic cell nucleus transfer-cloned embryos in pigs. — Han J, Yoo I, Lee S, Jung W, Kim HJ, Hyun SH et al. Theriogenology (2019)
    9. [9]
      Endometrial biopsy in Bos indicus beef heifers. — Ramirez-Garzon O, Satake N, Lyons RE, Hill J, Holland MK, McGowan M Reproduction in domestic animals = Zuchthygiene (2017)
    10. [10]
      Resident Macrophages and Lymphocytes in the Canine Endometrium. — Pires MA, Payan-Carreira R Reproduction in domestic animals = Zuchthygiene (2015)
    11. [11]
      Remodeling of bovine endometrium throughout the estrous cycle. — Arai M, Yoshioka S, Tasaki Y, Okuda K Animal reproduction science (2013)
    12. [12]
      Regulation of the hyaluronan system in ovine endometrium by ovarian steroids. — Raheem KA, Marei WF, Mifsud K, Khalid M, Wathes DC, Fouladi-Nashta AA Reproduction (Cambridge, England) (2013)
    13. [13]
      Expression of survivin, Bcl-2 and Bax proteins in the domestic cat (Felis catus) endometrium during the oestrus cycle. — Liman N, Alan E, Bayram GK, Gürbulak K Reproduction in domestic animals = Zuchthygiene (2013)
    14. [14]
      Bidirectional interaction between unfolded-protein-response key protein HSPA5 and estrogen signaling in human endometrium. — Guzel E, Basar M, Ocak N, Arici A, Kayisli UA Biology of reproduction (2011)
    15. [15]
      Modeling human endometrial decidualization from the interaction between proteome and secretome. — Garrido-Gomez T, Dominguez F, Lopez JA, Camafeita E, Quiñonero A, Martinez-Conejero JA et al. The Journal of clinical endocrinology and metabolism (2011)
    16. [16]
      Microarray analysis of equine endometrium at days 8 and 12 of pregnancy. — Merkl M, Ulbrich SE, Otzdorff C, Herbach N, Wanke R, Wolf E et al. Biology of reproduction (2010)
    17. [17]
      G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. — Kolkova Z, Noskova V, Ehinger A, Hansson S, Casslén B Molecular human reproduction (2010)
    18. [18]
      Expression and regulation of cholesterol sulfotransferase (SULT2B1b) in human endometrium. — Koizumi M, Momoeda M, Hiroi H, Hosokawa Y, Tsutsumi R, Osuga Y et al. Fertility and sterility (2010)
    19. [19]
      DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen. — Yamagata Y, Asada H, Tamura I, Lee L, Maekawa R, Taniguchi K et al. Human reproduction (Oxford, England) (2009)
    20. [20]
      Haemoglobin expression in human endometrium. — Dassen H, Kamps R, Punyadeera C, Dijcks F, de Goeij A, Ederveen A et al. Human reproduction (Oxford, England) (2008)
    21. [21]
      Decidualized and pre-decidualized normal endometrial stromal cells produce more O-linked N-acetylglucosamine containing epitope H than non-decidualized normal endometrial stromal cells. — Polyzos PT, Arvanitis LD, Charchanti A, Galani V, Havaki S, Kallioras VA et al. Histology and histopathology (2006)
    22. [22]
      The cytokine receptor gp130 and its soluble form are under hormonal control in human endometrium and decidua. — Classen-Linke I, Müller-Newen G, Heinrich PC, Beier HM, von Rango U Molecular human reproduction (2004)
    23. [23]
      Differential expression of angiopoietins 1 and 2 and their receptor Tie-2 in human endometrium. — Hirchenhain J, Huse I, Hess A, Bielfeld P, De Bruyne F, Krüssel JS Molecular human reproduction (2003)
    24. [24]
      Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. — Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V et al. Archives of gynecology and obstetrics (2003)
    25. [25]
      Somatostatin receptor 2 expression in the human endometrium through the menstrual cycle. — Green VL, Richmond I, Maguiness S, Robinson J, Helboe L, Adams IP et al. Clinical endocrinology (2002)
    26. [26]
      Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. — Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO et al. The Journal of clinical endocrinology and metabolism (2001)
    27. [27]
      Polo-like kinase expression in normal human endometrium during the menstrual cycle. — Takai N, Miyazaki T, Miyakawa I, Hamanaka R Reproduction, fertility, and development (2000)
    28. [28]
      Expression of integrin messenger ribonucleic acid in human endometrium: a quantitative reverse transcription polymerase chain reaction study. — Dou Q, Williams RS, Chegini N Fertility and sterility (1999)
    29. [29]
      Cyclic modulation of integrin expression in bovine endometrium. — Kimmins S, MacLaren LA Biology of reproduction (1999)
    30. [30]
      Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo. — Critchley HO, Tong S, Cameron ST, Drudy TA, Kelly RW, Baird DT Journal of reproduction and fertility (1999)
    31. [31]
      Tissue inhibitor of metalloproteinases (TIMP)-1, -2 and -3 in human endometrium during the menstrual cycle. — Zhang J, Salamonsen LA Molecular human reproduction (1997)
    32. [32]
      Cell-type expression, immunolocalization, and deoxyribonucleic acid-binding activity of basic transcription element binding transcription factor, an Sp-related family member, in porcine endometrium of pregnancy. — Wang Y, Michel FJ, Wing A, Simmen FA, Simmen RC Biology of reproduction (1997)
    33. [33]
      Type 1 angiotensin II receptors in human endometrium. — Saridogan E, Djahanbakhch O, Puddefoot JR, Demetroulis C, Dawda R, Hall AJ et al. Molecular human reproduction (1996)
    34. [34]
      Androgen receptor content in human endometrium. — Mertens HJ, Heineman MJ, Koudstaal J, Theunissen P, Evers JL European journal of obstetrics, gynecology, and reproductive biology (1996)
    35. [35]
      Quantitative analysis of T lymphocyte subsets in pregnant and nonpregnant human endometrium. — Vassiliadou N, Bulmer JN Biology of reproduction (1996)
    36. [36]
      Expression of vigilin in the uterus of ovariectomized steroid-treated rats and during the estrous cycle. — Rumpel E, Kruse C, Müller PK, Kühnel W Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft (1996)
    37. [37]
      I. Aging of the human endometrium: a basic morphological and immunohistochemical study. — Noci I, Borri P, Chieffi O, Scarselli G, Biagiotti R, Moncini D et al. European journal of obstetrics, gynecology, and reproductive biology (1995)
    38. [38]
      Immunohistochemical localization of C9 neoantigen and the terminal complement inhibitory protein CD59 in human endometrium. — Ratnoff WD, Brockman WW, Hasty LA American journal of reproductive immunology (New York, N.Y. : 1989) (1995)
    39. [39]
      Estrous cycle-related alterations in the expression of glycoconjugates and lectins in the mouse endometrium shown histochemically. — Akif F, Gabius HJ, Danguy A Tissue & cell (1995)
    40. [40]
      Immunohistochemical localization of heat shock proteins HSP70 and HSP90 in the human endometrium: correlation with sex steroid receptors and Ki-67 antigen expression. — Koshiyama M, Konishi I, Nanbu K, Nanbu Y, Mandai M, Komatsu T et al. The Journal of clinical endocrinology and metabolism (1995)
    41. [41]
      Endothelin-1 and endothelin receptors are present in the sheep uterus and conceptus at implantation. — Riley SC, Findlay JK, Salamonsen LA The Journal of endocrinology (1995)
    42. [42]
      Gene expression of epidermal growth factor in human endometrium during decidualization. — Sakakibara H, Taga M, Saji M, Kida H, Minaguchi H The Journal of clinical endocrinology and metabolism (1994)
    43. [43]
      Identification and immunolocalization of proteins synthesized by dog endometrium and membranes. — Buhi WC, Shille VM, Thatcher MJ, Alvarez IM, Qiu YX Journal of reproduction and fertility. Supplement (1993)
    44. [44]
      Tenascin expression in normal and abnormal human endometrium. — Sasano H, Nagura H, Watanabe K, Ito K, Tsuiki A, Sato S et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (1993)
    45. [45]
      Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. — Hunt JS, Chen HL, Hu XL, Tabibzadeh S Biology of reproduction (1992)
    46. [46]
      Endometrial immunoreactive beta-endorphin increases during mid-estrous cycle and early pregnancy in gilts. — Li WI, Wu H, Chen CL Biology of reproduction (1992)
    47. [47]
      The distribution of type-2 chain histo-blood group antigens in normal cycling human endometrium. — Ravn V, Teglbjaerg CS, Mandel U, Dabelsteen E Cell and tissue research (1992)
    48. [48]
      Immunocytochemical localization of oestrogen receptors in the endometrium of the ewe. — Cherny RA, Salamonsen LA, Findlay JK Reproduction, fertility, and development (1991)
    49. [49]
      Endometrium--an extragonadal source of inhibin. — Garde SV, Sheth AR, Zaveri BJ, Shah J, Hinduja I Indian journal of experimental biology (1991)
    50. [50]
      P-glycoprotein expression is increased in human secretory and gestational endometrium. — Axiotis CA, Guarch R, Merino MJ, Laporte N, Neumann RD Laboratory investigation; a journal of technical methods and pathology (1991)
    51. [51]
      Distribution of histological lesions in the equine endometrium. — Waelchli RO, Winder NC The Veterinary record (1989)
    52. [52]
      Differences in lectin binding patterns of normal human endometrium between proliferative and secretory phases. — Aoki D, Kawakami H, Nozawa S, Udagawa Y, Iizuka R, Hirano H Histochemistry (1989)
    53. [53]
      An insulin-like growth factor-binding protein in the baboon (Papio anubis) endometrium: synthesis, immunocytochemical localization, and hormonal regulation. — Fazleabas AT, Jaffe RC, Verhage HG, Waites G, Bell SC Endocrinology (1989)
    54. [54]
      The cytology of the normal cyclic endometrium. — Coscia-Porrazzi LO, Maiello FM, de Falco ML Diagnostic cytopathology (1986)
    55. [55]
      Histochemical localization of estrogen induced sulfated glycoprotein in rabbit uterus. — Endo M, Mori T, Yamasaki M, Yosizawa Z Histochemistry (1976)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG